Spyre Therapeutics, Inc. (SYRE) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Waltham, MA, United States. Le PDG actuel est Cameron Turtle.
SYRE a date d'introduction en bourse 2016-04-07, 73 employés à temps plein, cotée sur le NASDAQ Capital Marke, une capitalisation boursière de $3.87B.
Spyre Therapeutics, Inc. is a preclinical-stage biotechnology company focused on developing innovative therapies for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The company's lead candidate, SPY001, is a human monoclonal antibody targeting the α4β7 integrin, designed to selectively treat IBD patients. Spyre's pipeline also includes SPY002, which targets tumor necrosis factor-like ligand 1A, along with several combination and early-stage programs such as SPY003 (anti-IL-23), SPY004, and various combination therapies currently in preclinical development. Incorporated in 2013 and headquartered in Waltham, Massachusetts, the company was formerly known as Aeglea BioTherapeutics before rebranding to Spyre Therapeutics in November 2023.
